
|Articles|February 1, 2003
Established Paradigm
Paris - Combination immunotherapy for psoriasis is coming into the clinic. Experience is showing it can be a valuable strategy for increasing efficacy while minimizing toxicity, both acutely and potentially over the longer term, Christopher E.M. Griffiths, M.D., said at the World Congress of Dermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
3
Dermatology Conferences and Meetings Calendar: December 2025
4
ICYMI: First Patient Dosed in Global Phase 2 Study of Oral TYK2 Inhibitor Soficitinib for PN
5


















